Categories Earnings, Health Care
Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19
The company is working on AdCOVID, an intranasal vaccine candidate for protection from COVID-19
Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The drop in revenues was caused by lower billings under the US government contracts.
Net loss attributed to common stockholders for the year was $20.97 million, or $1.60 per share, versus $42.48 million, or $15.16 per share, last year. Last year’s results were impacted by an impairment charge of $24.9 million.
Analysts had projected a loss of $1.52 per share on revenue of $5.9 million for the year. Shares were down 6.4% in premarket hours on Friday.
R&D expenses decreased to $17.8 million from $18.5 million last year due to lower manufacturing and clinical trial costs on existing programs.
Altimmune announced that it has begun developing AdCOVID, an intranasal vaccine candidate for protection from COVID-19. The company said its vaccine candidate is capable of remaining stable under room temperature thus avoiding the need for cold chain shipping. This makes distribution easier among communities.
The company plans to begin animal testing in the second quarter of 2020 and is working to push the candidate towards a Phase 1 clinical trial as early as the third quarter of this year.
In 2019, Altimmune acquired Spitfire Pharma, Inc. including the product candidate ALT-801 indicated for the treatment of non-alcoholic steatohepatitis (NASH). The company expects to begin a Phase 1 clinical trial in 2020.
Altimmune also received $3.7 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA). This funding will support the Phase 1b clinical trial of NasoShield this year to evaluate alternative methods of intranasal dosing in humans.
At December 31, 2019, the company had cash, cash equivalents and short-term investments of $37.3 million.
Altimmune’s stock has gained 80% over the past three months and 10% over the past week.
Most Popular
Earnings Preview: UnitedHealth looks poised to end FY24 on a positive note
UnitedHealth Group (NYSE: UNH), a leading provider of health insurance and healthcare services, is expected to report fourth-quarter earnings next week. The company, a market leader in the nation's colossal
Mattel (MAT): A look at the toymaker’s evolving strategy and its opportunities
Shares of Mattel, Inc. (NASDAQ: MAT) stayed green on Wednesday. The stock has dropped 4% over the past month. Over the past few years, the toymaker has been focused on
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%. Net loss, excluding special items, was $0.04 per